KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
Jan 22, 2016 $1.71 $1.75 $1.67 $1.73 185 400
Jan 21, 2016 $1.60 $1.75 $1.59 $1.70 159 900
Jan 20, 2016 $1.46 $1.69 $1.40 $1.60 332 000
Jan 19, 2016 $1.70 $1.72 $1.45 $1.54 455 900
Jan 15, 2016 $1.70 $1.71 $1.58 $1.65 322 000
Jan 14, 2016 $1.61 $1.80 $1.48 $1.75 480 300
Jan 13, 2016 $1.93 $2.00 $1.58 $1.66 504 100
Jan 12, 2016 $1.95 $2.04 $1.81 $1.87 588 400
Jan 11, 2016 $2.36 $2.42 $1.92 $1.94 923 800
Jan 08, 2016 $2.53 $2.58 $2.25 $2.29 870 000
Jan 07, 2016 $2.80 $2.81 $2.36 $2.46 1 618 100
Jan 06, 2016 $3.67 $4.05 $2.84 $2.88 12 155 500
Jan 05, 2016 $2.92 $3.01 $2.84 $2.87 90 900
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT